Indian generics makers on a roll

Indian generics makers are on a roll. Yesterday, a Ranbaxy-Ipca Laboratories unit got the OK to make generic Metformin; today, a Sun Pharmaceuticals subsidiary won a tentative FDA for its version of Prandin, a type 2 diabetes drug originally made by Novo Nordisk.

Caraco Pharmaceutical Laboratories, based in Detroit, says it's first out of the chute with generic repaglinide, and it's hoping for 180-day marketing exclusivity. The approval is contingent on Caraco's resolution of any patent issues with Novo Nordisk, now under litigation.

- read the report from the Detroit Free Press

Related Articles:
Patent 'cliff' looms for Big Pharma. Report
Indian court spurns Novartis on patent challenge. Report
Generic competition slashes prices. Report
India's biotech future is bright. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.